Logo image of AUTL

AUTOLUS THERAPEUTICS PLC (AUTL) Stock Fundamental Analysis

NASDAQ:AUTL - Nasdaq - US05280R1005 - ADR - Currency: USD

2.31  -0.06 (-2.53%)

After market: 2.2401 -0.07 (-3.03%)

Fundamental Rating

3

Overall AUTL gets a fundamental rating of 3 out of 10. We evaluated AUTL against 551 industry peers in the Biotechnology industry. The financial health of AUTL is average, but there are quite some concerns on its profitability. AUTL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AUTL has reported negative net income.
In the past year AUTL has reported a negative cash flow from operations.
In the past 5 years AUTL always reported negative net income.
In the past 5 years AUTL always reported negative operating cash flow.
AUTL Yearly Net Income VS EBIT VS OCF VS FCFAUTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of AUTL (-29.57%) is better than 66.79% of its industry peers.
Looking at the Return On Equity, with a value of -59.46%, AUTL is in the better half of the industry, outperforming 60.25% of the companies in the same industry.
Industry RankSector Rank
ROA -29.57%
ROE -59.46%
ROIC N/A
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
AUTL Yearly ROA, ROE, ROICAUTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

AUTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AUTL Yearly Profit, Operating, Gross MarginsAUTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AUTL has an improved debt to assets ratio.
AUTL Yearly Shares OutstandingAUTL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
AUTL Yearly Total Debt VS Total AssetsAUTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.35, we must say that AUTL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.35, AUTL perfoms like the industry average, outperforming 56.62% of the companies in the same industry.
AUTL has a Debt/Equity ratio of 0.68. This is a neutral value indicating AUTL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.68, AUTL is not doing good in the industry: 75.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -1.35
ROIC/WACCN/A
WACC8.13%
AUTL Yearly LT Debt VS Equity VS FCFAUTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

AUTL has a Current Ratio of 9.24. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
AUTL has a Current ratio of 9.24. This is in the better half of the industry: AUTL outperforms 76.41% of its industry peers.
AUTL has a Quick Ratio of 9.02. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
AUTL has a Quick ratio of 9.02. This is in the better half of the industry: AUTL outperforms 75.14% of its industry peers.
Industry RankSector Rank
Current Ratio 9.24
Quick Ratio 9.02
AUTL Yearly Current Assets VS Current LiabilitesAUTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.45% over the past year.
The Revenue has grown by 496.00% in the past year. This is a very strong growth!
Measured over the past years, AUTL shows a very strong growth in Revenue. The Revenue has been growing by 28.31% on average per year.
EPS 1Y (TTM)26.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%-10.99%

3.2 Future

Based on estimates for the next years, AUTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.66% on average per year.
Based on estimates for the next years, AUTL will show a very strong growth in Revenue. The Revenue will grow by 120.47% on average per year.
EPS Next Y-6.92%
EPS Next 2Y3.28%
EPS Next 3Y10.52%
EPS Next 5Y19.66%
Revenue Next Year348.5%
Revenue Next 2Y210.47%
Revenue Next 3Y173.77%
Revenue Next 5Y120.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AUTL Yearly Revenue VS EstimatesAUTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
AUTL Yearly EPS VS EstimatesAUTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AUTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUTL Price Earnings VS Forward Price EarningsAUTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUTL Per share dataAUTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3Y10.52%

More info and screens

0

5. Dividend

5.1 Amount

AUTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL (8/6/2025, 4:51:17 PM)

After market: 2.2401 -0.07 (-3.03%)

2.31

-0.06 (-2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners84.29%
Inst Owner Change0.25%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap614.78M
Analysts85.88
Price Target9.86 (326.84%)
Short Float %6.4%
Short Ratio6.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.19%
Min EPS beat(2)-1.96%
Max EPS beat(2)52.34%
EPS beat(4)1
Avg EPS beat(4)-0.61%
Min EPS beat(4)-41.83%
Max EPS beat(4)52.34%
EPS beat(8)1
Avg EPS beat(8)-52.57%
EPS beat(12)4
Avg EPS beat(12)-32.96%
EPS beat(16)7
Avg EPS beat(16)-23.19%
Revenue beat(2)1
Avg Revenue beat(2)113.73%
Min Revenue beat(2)-99.05%
Max Revenue beat(2)326.5%
Revenue beat(4)1
Avg Revenue beat(4)6.86%
Min Revenue beat(4)-100%
Max Revenue beat(4)326.5%
Revenue beat(8)1
Avg Revenue beat(8)-30.47%
Revenue beat(12)4
Avg Revenue beat(12)129.45%
Revenue beat(16)5
Avg Revenue beat(16)139.38%
PT rev (1m)0%
PT rev (3m)-1.43%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)7.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)145.72%
Revenue NY rev (1m)1.87%
Revenue NY rev (3m)51.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.75
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0.04
BVpS1.39
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.57%
ROE -59.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 519.47%
Cap/Sales 420.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.24
Quick Ratio 9.02
Altman-Z -1.35
F-Score1
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)254.9%
Cap/Depr(5y)225.76%
Cap/Sales(3y)387.17%
Cap/Sales(5y)479.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-6.92%
EPS Next 2Y3.28%
EPS Next 3Y10.52%
EPS Next 5Y19.66%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%-10.99%
Revenue Next Year348.5%
Revenue Next 2Y210.47%
Revenue Next 3Y173.77%
Revenue Next 5Y120.47%
EBIT growth 1Y-37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.56%
EBIT Next 3Y9.66%
EBIT Next 5Y22.93%
FCF growth 1Y-112.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.61%
OCF growth 3YN/A
OCF growth 5YN/A